Abstract
Purpose
Clinical target volumes (CTV) and organs at risk (OAR) could be auto-contoured to save workload. The goal of this study was to assess a convolutional neural network (CNN) for totally automatic and accurate CTV and OAR in prostate cancer, while also comparing anticipated treatment plans based on auto-contouring CTV to clinical plans.
Methods
From January 2013 to January 2019, 217 computed tomography (CT) scans of patients with locally advanced prostate cancer treated at our hospital were collected and analyzed. CTV and OAR were delineated with a deep learning based method, which named CUNet. The performance of this strategy was evaluated using the mean Dice similarity coefficient (DSC), 95th percentile Hausdorff distance (95HD), and subjective evaluation. Treatment plans were graded using predetermined evaluation criteria, and % errors for clinical doses to the planned target volume (PTV) and organs at risk(OARs) were calculated.
Results
The defined CTVs had mean DSC and 95HD values of 0.84 and 5.04 mm, respectively. For one patient's CT scans, the average delineation time was less than 15 seconds. When CTV outlines from CUNetwere blindly chosen and compared to GT, the overall positive rate in clinicians A and B was 53.15% vs 46.85%, and 54.05% vs 45.95%, respectively (P>0.05), demonstrating that our deep machine learning model performed as good as or better than human demarcation Furthermore, 8 testing patients were chosen at random to design the predicted plan based on the auto-courtoring CTV and OAR, demonstrating acceptable agreement with the clinical plan: average absolute dose differences of D2, D50, D98, Dmean for PTV are within 0.74%, and average absolute volume differences of V45, V50 for OARs are within 3.4%. Without statistical significance (p>0.05), the projected findings are comparable to clinical truth.
Conclusion
The experimental results show that the CTV and OARs defined by CUNet for prostate cancer were quite close to the ground reality.CUNet has the potential to cut radiation oncologists' contouring time in half. When compared to clinical plans, the differences between estimated doses to CTV and OAR based on auto-courtoring were small, with no statistical significance, indicating that treatment planning for prostate cancer based on auto-courtoring has potential.